September 2026—The New York State Clinical Laboratory Evaluation Program has approved Quest Diagnostics’ Haystack MRD test. The circulating tumor DNA liquid biopsy test is for use in identifying residual or recurring disease in patients with a range of solid tumor cancers. With this approval, the test is now authorized for patient testing in all 50 U.S. states.
Quest Diagnostics, 800-222-0446